[go: up one dir, main page]

AR126089A1 - Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas - Google Patents

Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas

Info

Publication number
AR126089A1
AR126089A1 ARP220101496A ARP220101496A AR126089A1 AR 126089 A1 AR126089 A1 AR 126089A1 AR P220101496 A ARP220101496 A AR P220101496A AR P220101496 A ARP220101496 A AR P220101496A AR 126089 A1 AR126089 A1 AR 126089A1
Authority
AR
Argentina
Prior art keywords
fucosidase
glycosylated protein
recombinant glycosylated
level
protein
Prior art date
Application number
ARP220101496A
Other languages
English (en)
Inventor
Namratha Subhash
yu cong Chen
Kyle Shamus Melearney
Glen Bolton
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR126089A1 publication Critical patent/AR126089A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01051Alpha-L-fucosidase (3.2.1.51)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Reivindicación 1: Un método para obtener una proteína glucosilada recombinante que tiene niveles aumentados de glucoformas afucosiladas, comprendiendo el método 1) incubar una proteína glucosilada recombinante purificada con una fucosidasa humana de amplia especificidad en un tampón adecuado para la actividad fucosidasa durante un tiempo y en condiciones adecuadas para aumentar la afucosilación de la proteína glucosilada recombinante; y 2) separar la proteína glucosilada recombinante que tiene niveles aumentados de glucoformas afucosiladas de la fucosidasa; en donde la proteína glucosilada recombinante no reacciona con una glucosiltransferasa o sialiltransferasa. Reivindicación 3: El método de la reivindicación 1 o 2, en donde la fucosidasa está presente a un nivel entre 1000 U/mmol y 100,000 U/mmol de proteína glucosilada recombinante. Reivindicación 5: El método de cualquiera de las reivindicaciones 1 a 4, en donde dicha incubación es durante entre 1 hora y 24 horas. Reivindicación 6: El método de cualquiera de las reivindicaciones 1 a 5, en donde el tampón tiene un pH de aproximadamente 4.0 a aproximadamente 5.0. Reivindicación 7: El método de cualquiera de las reivindicaciones 1 a 6, en donde la temperatura se selecciona de una temperatura entre 30ºC y 40ºC. Reivindicación 10: El método de cualquiera de las reivindicaciones 1 a 9, en donde la proteína glucosilada recombinante purificada está en una cantidad de al menos 10 g/l. Reivindicación 11: El método de cualquiera de las reivindicaciones 1 a 10, en donde dicha fucosidasa se inmoviliza en una fase sólida. Reivindicación 12: El método de la reivindicación 11, en donde la fase sólida es una resina de cromatografía de proteína A.
ARP220101496A 2021-06-07 2022-06-06 Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas AR126089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163197908P 2021-06-07 2021-06-07

Publications (1)

Publication Number Publication Date
AR126089A1 true AR126089A1 (es) 2023-09-13

Family

ID=82482930

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101496A AR126089A1 (es) 2021-06-07 2022-06-06 Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas

Country Status (9)

Country Link
US (1) US20240279704A1 (es)
EP (1) EP4352094A1 (es)
JP (1) JP2024521219A (es)
AR (1) AR126089A1 (es)
AU (1) AU2022289365A1 (es)
CA (1) CA3222409A1 (es)
MX (1) MX2023014515A (es)
TW (1) TW202317614A (es)
WO (1) WO2022261021A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4677079A2 (en) * 2023-03-08 2026-01-14 Vib Vzw Fucosidase enzymes for therapeutic applications

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US6630143B1 (en) 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
ES2144386T5 (es) 1996-12-23 2012-12-07 Immunex Corporation Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
NZ500253A (en) 1997-04-16 2002-09-27 Amgen Inc Osteoprotegerin binding proteins and receptors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
CA2315251A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
AU755391B2 (en) 1997-12-23 2002-12-12 Immunex Corporation SIGIRR DNA and polypeptides
WO1999033878A1 (en) 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
EP1049777B1 (en) 1998-01-23 2005-08-03 Immunex Corporation Acpl dna and polypeptides
NZ510357A (en) 1998-08-07 2004-02-27 Immunex Corp Molecules designated B7L-1
DE69942861D1 (de) 1998-08-07 2010-11-25 Immunex Corp Ldcam genannte moleküle
JP4454859B2 (ja) 1998-11-13 2010-04-21 イミュネックス・コーポレーション ヒトtslpdnaおよびポリペプチド
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU2001272925A1 (en) 2000-05-26 2001-12-11 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
WO2002020762A2 (en) 2000-09-05 2002-03-14 Amgen Inc. Tnf receptor-like molecules and uses thereof
MX349009B (es) 2001-01-05 2017-07-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP1448588A4 (en) 2001-10-23 2006-10-25 Psma Dev Company L L C ANTIBODIES AND MULTIMERS OF PSMA PROTEINS
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2467738A1 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
AU2002351204B2 (en) 2001-12-03 2008-07-10 Abgenix, Inc. Anti-CD45RB antibodies for use in treating autoimmune disease and transplant rejection
DE60220719T2 (de) 2001-12-28 2008-03-06 Amgen Fremont Inc. Antikörper gegen das muc18-antigen
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
EP1467757B1 (en) 2001-12-28 2008-05-07 Amgen Fremont Inc. Use of antibodies against the muc18 antigen
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
UA87979C2 (ru) 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
AU2003298816C1 (en) 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
EP2457587A1 (en) 2003-06-27 2012-05-30 Amgen Fremont Inc. Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
TWI385180B (zh) 2003-07-15 2013-02-11 安美基公司 作為選擇性神經生長因子(ngf)通道抑制劑之人類抗-ngf中和抗體
EP1648935A2 (en) 2003-07-25 2006-04-26 Amgen Inc. Antagonists and agonists of ldcam and methods of use
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
DE60325906D1 (de) 2003-08-08 2009-03-05 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1692184B1 (en) 2003-11-07 2012-03-07 Immunex Corporation Antibodies that bind interleukin-4 receptor
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
ES2362667T3 (es) 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
US7449555B2 (en) 2004-04-23 2008-11-11 Amgen Inc. Antibodies of angiogenesis inhibiting domains CD148
WO2005118643A2 (en) 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of cd148
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Il−13に対する完全ヒトモノクローナル抗体
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
EP1868647A4 (en) 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
EA015534B1 (ru) 2005-04-25 2011-08-30 Пфайзер Инк. Антитела к миостатину и способы их применения
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2397497A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
DOP2006000195A (es) 2005-09-07 2017-08-15 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
HRP20120421T1 (hr) 2005-12-13 2012-07-31 Medimmune@Limited Vezni proteini specifični za inzulinu slične čimbenike rasta i njihova upotreba
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之c-kit抗體
EP2035454A2 (en) 2006-05-19 2009-03-18 Amgen, Inc. Antibodies to sars coronavirus
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
SG182985A1 (en) 2007-04-02 2012-08-30 Amgen Fremont Inc Anti-ige antibodies
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
WO2009009086A2 (en) 2007-07-12 2009-01-15 Sangamo Biosciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
EP2592093A1 (en) 2007-08-21 2013-05-15 Amgen, Inc Human c-fms antigen binding proteins
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α4β7雜二聚體專一性拮抗抗體
KR101641526B1 (ko) 2009-06-02 2016-07-21 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
RU2017122482A (ru) 2010-08-05 2019-01-30 Сиэтл Дженетикс, Инк. Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
CN104220603B (zh) * 2012-02-10 2017-06-06 马里兰大学,巴尔的摩 抗体及其Fc片段的化学酶法糖基化工程
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
TWI682033B (zh) 2014-03-17 2020-01-11 泉盛生物科技股份有限公司 製造具有經修飾的糖苷化作用之重組糖蛋白之方法
CA2950577A1 (en) * 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
EP3194583B1 (en) 2014-07-30 2021-09-15 Zumutor Biologics, Inc. Non-fucosylated protein and methods thereof
WO2016075662A2 (en) 2014-11-15 2016-05-19 Zumutor Biologics, Inc. Dna-binding domain, non-fucosylated and partially fucosylated proteins, and methods thereof
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
JP6587696B2 (ja) 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
EP3371206B1 (en) 2015-11-02 2021-04-14 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
CN109715819A (zh) 2016-08-10 2019-05-03 马里兰大学帕克分校 设计者α1,6-岩藻糖苷酶突变体实现完整N-糖肽和N-糖蛋白的直接核心岩藻糖基化
TWI727884B (zh) 2016-08-24 2021-05-11 醣基生醫股份有限公司 利用醣苷內切酶突變體重塑醣蛋白及其使用方法
EP3339444A1 (en) 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US10260056B2 (en) * 2017-03-17 2019-04-16 New England Biolabs, Inc. Cleavage of fucose in N-glycans
CN107881160A (zh) 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CN110373374B (zh) 2018-04-12 2023-07-07 上海颢哲信息科技有限公司 一种降低抗体核心岩藻糖基化的方法和组合物
AU2019274782A1 (en) 2018-05-24 2020-12-03 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
JP2021528074A (ja) 2018-06-20 2021-10-21 マサチューセッツ インスティテュート オブ テクノロジー 特徴的なグリカン構造を有するプロテオグリカンを糖鎖工学的に改変する方法
EP3833688A1 (en) 2018-08-10 2021-06-16 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
CN113166728A (zh) 2018-08-29 2021-07-23 联合生物制药股份有限公司 去岩藻醣基化抗体及其制造
BR112021003793A2 (pt) 2018-08-29 2021-05-18 United Biopharma Inc método para produzir uma proteína afucosilada em uma célula hospedeira
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CN114026229B (zh) * 2019-08-05 2025-03-25 醣基生医股份有限公司 用于重塑抗体醣型之融合蛋白

Also Published As

Publication number Publication date
MX2023014515A (es) 2024-01-29
EP4352094A1 (en) 2024-04-17
WO2022261021A1 (en) 2022-12-15
US20240279704A1 (en) 2024-08-22
CA3222409A1 (en) 2022-12-15
TW202317614A (zh) 2023-05-01
AU2022289365A1 (en) 2023-12-14
JP2024521219A (ja) 2024-05-28

Similar Documents

Publication Publication Date Title
Higgins et al. Gibberellic acid and abscisic acid modulate protein synthesis and mRNA levels in barley aleurone layers
Ohashi et al. A role for phosphatidylinositol transfer protein in secretory vesicle formation
DE69936105D1 (de) Menschliche tslp nukleinsäuren und polypeptide
IS8213A (is) Fjölpeptíð til að kalla fram verndandi ónæmissvörun gegn gullinni klasahnettlu
BRPI0410261A (pt) método de detecção de probnp natural
DE69435049D1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
SI1543106T1 (sl) Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice
ES2150573T3 (es) Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
BR0214653A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleìco, vetor de expressão recombinante, célula hospedeira recombinante, método para produzir um polipeptìdeo, cepa, uso de pelo menos uma protease, método para melhorar o valor nutricional de uma ração animal, aditivo para ração animal, composição de ração animal, e, método para o tratamento de proteìnas vegetais
ES2531155T3 (es) Cristalización de anticuerpos anti-VEGF
EA201490447A1 (ru) Эндогликозидаза из streptococcus pyogenes и способы с применением указанной эндогликозидазы
HUP9901640A2 (hu) Foszfolipáz aktivítású fehérje
AR126089A1 (es) Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
ATE73499T1 (de) Anti-protein c monoklonaler antikoerper, seine herstellung und verwendung.
ATE101162T1 (de) Durch cys-kodon modifizierte dns.
DE69836823D1 (de) Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
DK343284D0 (da) Termostabil alfa-amylase og fremgangsmaade til fremstilling heraf
KR940021579A (ko) 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법
Hartel et al. Rapid purification of dipeptidyl peptidase IV from rat liver plasma membrane
KR860007275A (ko) 모노클로날 항-알파-아밀라제 항체 및 그의 제법
BR112021006248A2 (pt) cepa mutante de trichoderma reesei e métodos para produzir uma proteína e para produzir uma celulase
KR970065724A (ko) 폴리펩티드의 제조방법
PE20220571A1 (es) Planta que comprende un nuevo glucosido de esteviol
Kim et al. Processing and subcellular localization of ADAM2 in the Macaca fascicularis testis and sperm
Carroll et al. A low-molecular-weight protein cross-reacting with human liver N-acetyl-β-d-glucosaminidase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal